LONDON, April 6, 2018 /PRNewswire/ --
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Report Details
This report provides analysis and evaluation of the current and potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new report you find 333-page report you will receive 53 tables and 88 figures- all unavailable elsewhere.
The 333-page report provides clear detailed insight into the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Provides a brief history of rheumatoid arthritis, treatment options, marketed drugs and pipeline products.
• Discusses the global pricing & reimbursement for therapeutic drugs, factors affecting pricing & reimbursement, price negotiations & discounts and reimbursement policies.
• Discusses Health Economics and Outcomes Research (HEOR), Economic Value Planning, Cost-Effectiveness analysis as well as patent expiry and effects on pricing.
• Discusses Health Technology Assessment (HTA) in market access, key benefits of HTA, HTA regulatory agencies.
• Discusses the healthcare system, healthcare expenditure, key formularies, role of pharmacists, regulatory & approval process, pricing & reimbursement process, HTA, cost of rheumatoid arthritis treatment and payer insight, of these national markets: • The US • Canada • United Kingdom • Germany • France • Italy • Spain • Japan • Australia • Brazil • Russia • India • China
• Discusses parallel import in the US and Europe
Visiongain's study is intended for anyone requiring commercial analyses for the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. You find data, trends and predictions.
Buy our report today Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on: https://www.visiongain.com/Report/2160/Rheumatoid-Arthritis-Pricing-Reimbursement-Market-Access-2018
List of Companies Mentioned in the Report
Abbott
AbbVie
Ablynx
Astellas
AstraZeneca
AVIVA Health Insurance
AXA
BMS
BUPA
Can-Fite BioPharma
Celltrion
Cipla
ClaimSecure
CVS Caremark
Eli Lilly
Empire Life
Express Script
Freedom Health Insurance
Galapagos
Gilead
Great West Life (GWL)
Green Shield
Helpucover Health Insurance
Janssen
Johnson & Johnson
Manulife
Medavie Blue Cross
Medicare International
MedImmune
Merck
Momenta Pharmaceuticals
MSD
National Friendly HealthCare
Pfizer
PruHealth
Roche
Saga Health Insurance
Sandoz
Sanford C. Bernstein & Company
Sanofi
Schering-Plough
Shanghai CP Guojian Pharmaceutical Co
Simply Health
TelusHealth
UCB
VitaerisBio
Wyeth
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India
Advertisement
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Report Details
This report provides analysis and evaluation of the current and potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new report you find 333-page report you will receive 53 tables and 88 figures- all unavailable elsewhere.
The 333-page report provides clear detailed insight into the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Provides a brief history of rheumatoid arthritis, treatment options, marketed drugs and pipeline products.
• Discusses the global pricing & reimbursement for therapeutic drugs, factors affecting pricing & reimbursement, price negotiations & discounts and reimbursement policies.
• Discusses Health Economics and Outcomes Research (HEOR), Economic Value Planning, Cost-Effectiveness analysis as well as patent expiry and effects on pricing.
• Discusses Health Technology Assessment (HTA) in market access, key benefits of HTA, HTA regulatory agencies.
• Discusses the healthcare system, healthcare expenditure, key formularies, role of pharmacists, regulatory & approval process, pricing & reimbursement process, HTA, cost of rheumatoid arthritis treatment and payer insight, of these national markets: • The US • Canada • United Kingdom • Germany • France • Italy • Spain • Japan • Australia • Brazil • Russia • India • China
• Discusses parallel import in the US and Europe
Visiongain's study is intended for anyone requiring commercial analyses for the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. You find data, trends and predictions.
Buy our report today Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on: https://www.visiongain.com/Report/2160/Rheumatoid-Arthritis-Pricing-Reimbursement-Market-Access-2018
List of Companies Mentioned in the Report
Abbott
AbbVie
Ablynx
Astellas
AstraZeneca
AVIVA Health Insurance
AXA
BMS
BUPA
Can-Fite BioPharma
Celltrion
Cipla
ClaimSecure
CVS Caremark
Eli Lilly
Empire Life
Express Script
Freedom Health Insurance
Galapagos
Gilead
Great West Life (GWL)
Green Shield
Helpucover Health Insurance
Janssen
Johnson & Johnson
Manulife
Medavie Blue Cross
Medicare International
MedImmune
Merck
Momenta Pharmaceuticals
MSD
National Friendly HealthCare
Pfizer
PruHealth
Roche
Saga Health Insurance
Sandoz
Sanford C. Bernstein & Company
Sanofi
Schering-Plough
Shanghai CP Guojian Pharmaceutical Co
Simply Health
TelusHealth
UCB
VitaerisBio
Wyeth
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
